Lower Brain-Derived Neurotropic Factor Levels in Untreated Adolescents With First-Episode Psychosis

Şimşek, Şeref; Gençoğlan, Salih; Yüksel, Tuğba; Kaplan, İbrahim; Aktaş, Hüseyin

doi:10.1097/jcp.0000000000000378

Cited by 18 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post mortem studies have revealed lower levels of BDNF mRNA in the prefrontal cortex (Perlman et al., 2004). Also, many in vivo studies have demonstrated lowered BDNF protein concentration in schizophrenia patient blood serum and plasma samples (Şimşek et al., 2015; Yoshimura et al., 2016). Li et al.…”

Section: Introductionmentioning

confidence: 99%

Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders

Valiulienė

Valiulis

Dapšys

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

Resistance to pharmacological treatment poses a notable challenge for psychiatry. Such cases are usually treated with brain stimulation techniques, including repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT). Empirical evidence links treatment resistance to insufficient brain plasticity and chronic inflammation. Therefore, this study encompasses analysis of neurotrophic and inflammatory factors in psychiatric patients undergoing rTMS and ECT in order to refine the selection of patients and predict clinical outcomes. This study enrolled 25 drug‐resistant depressive patients undergoing rTMS and 31 drug‐resistant schizophrenia patients undergoing ECT. Clinical efficacy of brain stimulation therapies was gauged using MADRS and HAM‐D scales in the depression group and PANSS scale in the schizophrenia group. Blood‐derived BDNF, VEGF, and TNFα were analysed during the treatment course. For reference, 19 healthy control subjects were also enrolled. After statistical analysis, no significant differences were detected in BDNF, VEGF, and TNFα concentrations among healthy, depressive, and schizophrenic subject groups before the treatment. However, depressive patient treatment with rTMS has increased BDNF concentration, while schizophrenic patient treatment with ECT has lowered the concentration of TNFα. Our findings suggest that a lower initial TNFα concentration could be a marker for treatment success in depressed patients undergoing rTMS, whereas in schizophrenic patient group treated with ECT, a higher concentration of VEGF correlates to milder symptoms post‐treatment, especially in the negative scale.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders

Valiulienė

Valiulis

Dapšys

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…The most recent one, by Singh et al, confirmed lower BDNF level for first‐episode psychosis patients with no effect for treatment regimen (Singh et al, 2020). Among the 29 studies included, only one, by Şimşek et al (2015), was performed on early‐onset population (mean age 14.6 ± 1.6) (Şimşek et al, 2015). Results of the study indicated lower serum level with no association to symptoms and duration of untreated psychosis.…”

Section: Discussionmentioning

confidence: 99%

Plasma biomarkers in adolescents with schizophrenia‐spectrum disorder

Zakowicz

Skibińska

Waśniewski

et al. 2023

Early Intervention Psych

View full text Add to dashboard Cite

AimSchizophrenia onset in the developmental age has a strong neurodevelopmental burden and is associated with a poorer prognosis. The approach to diagnosis is still based on symptomatic description without objective validation. In this study, we aimed to compare the peripheral blood levels of hypothesized biomarker proteins: brain‐derived neurotrophic factor (BDNF), proBDNF, p75 neurotrophin receptor (p75NTR) and S100B between early‐onset schizophrenia‐spectrum adolescents (n = 45) and healthy controls (n = 34).MethodsClinical assessment of the participants encompassed symptomatic description with the use of structured interviews and executive function objective measurement. Plasma levels of BDNF protein were significantly lower in schizophrenia patients than in controls both at admission (p = .003) and 6–8 weeks follow‐up (p = .007).ResultsWe observed significant correlations between BDNF, proBDNF and p75NTR levels and positive and negative symptoms scale (PANSS) scores, p75NTR and S100B levels and suicidal parameters, as well as a correlation of BDNF plasma level with the risky decision‐making style in Iowa Gambling Task (IGT).ConclusionsThe results indicate a potential value of studied proteins as a biomarker in the diagnosis and monitoring of the disease's course.

show abstract

“… 46 Indeed a longer DUP appears to be related to a worse short-term 47 and long-term clinical outcome 48 49 in SCZ individuals, as well as with lower BDNF serum levels, 50 although the latter finding has been not replicated in subsequent studies. 51 Other measures of illness severity, such as number of hospital admissions and type of clinical course will be collected for the analysis.…”

Section: Methodsmentioning

confidence: 99%

Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study

Primavera

Manchia²,

Deriu

et al. 2017

BMJ Open

View full text Add to dashboard Cite

IntroductionBrain-derived neurotrophic factor (BDNF) plays a crucial role in neurodevelopment, synaptic plasticity and neuronal function and survival. Serum and plasma BDNF levels are moderately, but consistently, decreased in patients with schizophrenia (SCZ) compared with healthy controls. There is a lack of knowledge, however, on the temporal manifestation of this decline. Clinical, illness course and treatment factors might influence the variation of BDNF serum levels in patients with psychosis. In this context, we propose a longitudinal study of a cohort of SCZ and schizophrenic and schizoaffective disorder (SAD) Sardinian patients with the aim of disentangling the relationship between peripheral BDNF serum levels and changes of psychopathology, cognition and drug treatments.Methods and analysisLongitudinal assessment of BDNF in Sardinian psychotic patients (LABSP) is a 24-month observational prospective cohort study. Patients with SAD will be recruited at the Psychiatry Research Unit of the Department of Medical Science and Public Health, University of Cagliari and University of Cagliari Health Agency, Cagliari, Italy. We will collect BDNF serum levels as well as sociodemographic, psychopathological and neurocognitive measures. Structured, semistructured and self-rating assessment tools, such as the Positive and Negative Syndrome Scale for psychopathological measures and the Brief Assessment of Cognition in Schizophrenia for cognitive function, will be used.Ethics and disseminationThis study protocol was approved by the University of Cagliari Health Agency Ethics Committee (NP2016/5491). The study will be conducted in accordance with the principles of good clinical practice, in the Declaration of Helsinki in compliance with the regulations. Participation will be voluntary and written informed consent will be obtained for each participant upon entry into the study. We plan to disseminate the results of our study through conference presentations and publication in international peer-reviewed journals. Access to raw data will be available in anonymised form upon request to the corresponding author.

show abstract

Lower Brain-Derived Neurotropic Factor Levels in Untreated Adolescents With First-Episode Psychosis

Abstract: High incidence of schizophrenia in patients with FEP suggests a relationship between BDNF levels and the pathogenesis of schizophrenia. We suggest that BDNF may be a useful neurobiological marker of early onset schizophrenia.

Cited by 18 publications

References 25 publications

Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders

Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders

Plasma biomarkers in adolescents with schizophrenia‐spectrum disorder

Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study

Contact Info

Product

Resources

About